Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 4, 2003 - Issue 6
Submit an article Journal homepage
107
Views
10
CrossRef citations to date
0
Altmetric
Drug Evaluation

Dofetilide: a new drug to control cardiac arrhythmia

Hanne Elming Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. [email protected]
,
Bente Brendorp Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. [email protected]
,
Ole Dyg Pedersen Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. [email protected]
,
Lars Køber Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. [email protected]
&
Christian Torp-Petersen Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. [email protected]
Pages 973-985 | Published online: 02 Mar 2005

Bibliography

  • RYDER KM, BENJAMIN EJ et al:Epidemiology and significance of atrialfibrillation. Am. J. Cardiol (1999) 84:131R–138R.
  • ••Nice review on atrial fibrillation.
  • BENJAMIN EJ, LEVY D, VAZIRI SM et al.: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.JAMA (1994) 271:840–844.
  • LEVY S, MAAREK M, COUMEL P et al: Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation (1999) 99:3028–3035.
  • FUSTER V, RYDEN LE, ASINGER RW et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur. Heart. J. (2001) 22:1852–1923.
  • ••Important guidelines.
  • TORP-PEDERSEN C, MOLLER M, BLOCH-THOMSEN PE etal.: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.New Engl. j Med(1999) 341:857–865.
  • ••A large clinical trial on dofetilide andmortality.
  • KOBER L, BLOCH THOMSEN PE, MOLLER M et al.: Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet (2000) 356:2052–2058.
  • ••A large clinical trial on dofetilide andmortality.
  • Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). TheCONSENSUS Trial Study Group.N. Engl. J. Med. (1987) 316:1429–1435.
  • MARU M: Atrial fibrillation and emboliccomplications. East Ali: Med. J. (1997) 74:3–5.
  • BENJAMIN EJ, WOLF PA,D'AGOSTINO RB et al: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation (1998) 98:946–952.
  • WYSE DG, LOVE JC, YAO Q et al: Atrial fibrillation: a risk factor for increased mortality-an AVID registry analysis. ?Interv. Card. Electrophysiol (2001) 5:267–273.
  • PEDERSEN OD, BAGGER H, KOBER L et al: The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. Trandolapril Cardiac Evaluation. Eur.Heart. J. (1999) 20:748–754.
  • HAMER ME, BLUMENTHAL JA, MCCARTHY EA et al.: Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia.Am. J. Cardiol (1994) 74:826–829.
  • WYSE DG, WALDO AL, DIMARCO JP et al: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl. J. Med. (2002) 347:1825–1833.
  • ••A clinical trial of great interest and impacton future treatment strategy.
  • The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation (1991) 84:1831–1851.
  • •A fine overview of antiarrhythmic agents: their mechanism of action and classification.
  • COPLEN SE, ANTMAN EM,BERLIN JA et al: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.Circulation (1990) 82:1106–1116.
  • Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cast investigators Cardiac Arrhythmia Suppression Trial (CAST). N. Engl. J. Med. (1989) 321(6):406–412.
  • ••A clinical trial with great impact on futuretreatment strategy.
  • Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl. J. Med. (1992) 327:227–233.
  • JUUL-MOLLER S,EDVARDSSON N,REHNQVIST-AHLBERG N et al: Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation (1990) 82:1932–1939.
  • THIBAULT B,NATTEL S: Optimal management with class I and class III antiarrhythmic drugs should be done in the outpatient setting: protagonist.Cardiovasc. Dectrophysiol (1999) 10:472–481.
  • WALDO AL, CAMM AJ, DERUYTER H etal.: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral D-sotalol.Lancet (1996) 348:7–12.
  • ••Clinical trial with possible great impact onfuture treatment strategy.
  • SUNDT TM 3rd, CAMILLO CJ, COX JL etal.: The maze procedure for cure of atrial fibrillation. Cardiol Chu. (1997) 15:739–748.
  • Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone trials meta-analysis investigators. Lancet (1997) 350:1417–1424.
  • GWILT M, ARROWSMITH JE, BLACKBURN KJ etal.: UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. Pharmacol Exp.Ther. (1991) 256:318–324.
  • SEDGWICK ML,RASMUSSEN HS, COBBE SM et al: Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris. Am.J. Cardiol (1992) 69:513–517.
  • SINGH S, ZOBLE RG, YELLEN L etal.: Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on 983Expert Op/n. Pharmacother. (2003) 4(6)dofetilide (SAFIRE-D) study. Circulation (2000) 102:2385–2390.
  • RASMUSSEN HS, ALLEN MJ, BLACKBURN KJ, BUTROUS GS, DALRYMPLE HW et al.: Dofetilide, a novel class III antiarrhythmic agent. Cardiovasc. Pharmacol (1992) 20\(Suppl. 2):S96–S105.
  • GWILT M, DALRYMPLE HW, BURGES RA et al: Electrophysiologic properties of UK-66,914, a novel class III antiarrhythmic agent. I Cardiovasc. Pharmacol. (1991) 17:376–385.
  • JURKIEWICZ NK,SANGUINETTI MC et al: Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ. Res (1993) 72:75–83.
  • ROUSSEAU MF, MASSART PE, VAN EYLL C et al.: Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure. Am. J. Cardiol (2001) 87:1250–1254.
  • BORIANI G, BIFFI M, BACCHI L et al:A randomised cross-over study on the haemodynamic effects of oral dofetilide compared with oral sotalol in patients with ischaemic heart disease and sustained ventricular tachycardia.Eur. Chu. Pharmacol (2002) 58:165–169.
  • TWEEDIE D, HENDERSON C, KANE K et al: Glibenclamide, but not class III drugs, prevents ischaemic shortening of the refractory period in guinea-pig hearts. Eur. I Pharmacol (1993) 240:251–257.
  • ANDERSEN HR, WIGGERS H, KNUDSEN LL et al: Dofetilide reduces the incidence of ventricular fibrillation during acute myocardial ischaemia. A randomised study in pigs.Cardiovasc. Res. (1994) 28:1635–1640.
  • KNILANS TK, LATHROP DA,NANASI PP et al.: Rate and concentration-dependent effects of UK-68,798, a potent new class III antiarrhythmic, on canine Purkinje fibre action potential duration and Vmax. Br. J. Pharmacol (1991) 103:1568–1572.
  • SEDGWICK ML, RASMUSSEN HS, COBBE SM etal.: Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. Am. J. Cardiol (1992) 70:1432–1437.
  • LE COZ F, FUNCK-BRENTANO C, MORELL T et al.: Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. Chu. PharmacolTher. (1995) 57:533–542.
  • SMITH DA, RASMUSSEN HS, STOPHER DA et al: Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xertobiotica (1992) 22:709–719.
  • GEMMILL JD, HOWIE CA, MEREDITH PA et al: A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers. Br. J. Chu. Pharmacol (1991) 32:429–432.
  • WALKER DK, ALABASTER CT, CONGRAVE GS et al: Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab. Dispos. (1996) 24:447–455.
  • GREENBAUM RA, CAMBELL TJ, CHANNE KS: EMERALD. Circulation (1998) 17:633-633 (Abstract).
  • PEDERSEN OD, BAGGER H,KELLER N et al.: Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigation of arrhythmia and mortality on dofetilide (DIAMOND) substudy. Circulation (2001) 104:292–296.
  • •An important sub-study of the DIAMOND study with specific focus on AE
  • TENDERA M, WNUK-WOJNAR AM, KULAKOWSKI P etal.: Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo. Am. Heart (2001) 142:93–98.
  • POOL PE, SINGH SN, FRIEDRICH T etal.: Effects of intravenous dofetilide in patients with frequent premature ventricular contractions: a clinical trial.Clin.Cardiol. (2000) 23:415–416.
  • BASHIR Y, THOMSEN PE, KINGMA JH et al: Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group.Am. J. Cardiol (1995) 76:1040–1044.
  • ECHT DS, LEE JT, MURRAY KT et al: A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias.Cardiovasc. Electrophysiol (1995) 6:687–699.
  • BORIANI G, LUBINSKI A, CAPUCCI Aet al.: A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide versus sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur. Heart J. (2001) 22:2180–2191.
  • MAZUR A, ANDERSON ME,BONNEY S,RODEN DM etal.: Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation. J. Am. Coll Cardiol (2001) 37:1100–1105.
  • BRENDORP B, ELMING H, JUN L et al: QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide.Circulation (2001) 103:1422–1427.
  • •Important substudy of the DIAMOND study with specific focus on the QT interval.
  • PRITCHETT EL,WILKINSON WE: Effect of dofetilide on survival in patients with supraventricular arrhythmias. Am. Heart J. (1999) 138:994–997.
  • KOBER L, TORP-PEDERSEN C, CARLSEN JE etal.: A clinical trial of the angiotensin-converting-enzyme inhibitor randolapril in patients with left ventricular Dysfunction After Myocardial Infarction. N Engl. J. Med. (1995) 333:1670–1676.
  • Pfizer Laboratories: Tikosyn" (dofetilide) Package insert. Pfizer Laboratories (1999).
  • LAPOINTE NM, KRAMER JM, WEINFURT KP,CALIFF RM et al: Practitioner acceptance of the dofetilide risk-management program. Pharmacotherapy (2002) 22:1041–1046.
  • BRENDORP B, ELMING H, JUN L et al: QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide.Circulation (2001) 103:1422–1427.
  • CRIJNS HJ, VAN GELDER IC, KINGMA JH etal.: Atrial flutter can be terminated by a class III antiarrhythmic 984Expert Op/n. Pharmacother. (2003) 4(6)drug but not by a class IC drug. Eur. Heart j. (1994) 15:1403–1408.
  • SEDGWICK ML, LIP G, RAE AP COBBESM et al.: Chemical cardioversion of atrial fibrillation with intravenous dofetilide. bit .j Cardiol (1995) 49:159–166.
  • FROST L, MORTENSEN PE, TIN GLEFF J et al.: Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group. Int.j. Cardiol (1997) 58:135–140.
  • FALK RH, POLLAK A, SINGH SN, FRIEDRICH T et al: Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. j. Am. Coll. Cardiol (1997) 29:385–390.
  • NORGAARD BL, WACHTELL K, CHRISTENSEN PD etal.: Efficacy and safety of intravenously administereddofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am. Heart j. (1999) 137:1062–1069.
  • LINDEBOOM JE, KINGMA JH, CRIJNS HJ, DUNSELMAN PH et al: Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter. Am. j Cardiol (2000) 85:1031–1033.
  • BIANCONI L, CASTRO A, DINELLI M et al: Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur. Heart j. (2000) 21:1265–1273.
  • COBBE SM, CAMPBELL RW, CAMM AJet al.: Effects of intravenous dofetilide on induction of atrioventricular re-entrant tachycardia. Heart (2001) 86:522–526.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.